NCT06937866 - Maintenance Zanzalintinib With Etoposide After HDCT in GCT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2032

Conditions

Germ Cell Tumor

Interventions

DRUG

Zanzalintinib

Three zanzalintinib doses of 40mg, 60mg or 100mg. The initial starting dose of zanzalintinib will be 40mg. The patients will receive zanzalintinib orally daily continuously for 28 day cycles.

DRUG

Etoposide Capsule

Oral daily for 21 days of each 28 day cycle.

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis